BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,933,096 | +0.6% | 555,522 | 0.0% | 1.21% | -58.1% |
| Q2 2023 | $3,910,875 | -15.6% | 555,522 | 0.0% | 2.88% | -35.7% |
| Q1 2023 | $4,633,053 | -31.0% | 555,522 | -5.1% | 4.48% | -20.0% |
| Q4 2022 | $6,718,027 | -18.9% | 585,194 | -33.9% | 5.60% | +19.1% |
| Q3 2022 | $8,284,000 | +17.6% | 885,194 | -7.2% | 4.71% | +119.9% |
| Q2 2022 | $7,046,000 | -75.9% | 953,994 | -58.0% | 2.14% | -63.0% |
| Q1 2022 | $29,242,000 | +19.2% | 2,270,733 | -4.2% | 5.78% | +65.9% |
| Q4 2021 | $24,523,000 | -11.7% | 2,370,733 | +14.5% | 3.48% | +0.8% |
| Q3 2021 | $27,777,000 | -8.5% | 2,070,733 | +7.8% | 3.46% | -17.4% |
| Q2 2021 | $30,367,000 | +26.1% | 1,920,733 | -18.9% | 4.18% | +16.1% |
| Q1 2021 | $24,079,000 | +8.4% | 2,367,670 | -20.6% | 3.61% | +29.6% |
| Q4 2020 | $22,207,000 | +156.0% | 2,980,870 | +18.0% | 2.78% | +143.5% |
| Q3 2020 | $8,676,000 | -9.0% | 2,525,857 | +26.3% | 1.14% | -5.5% |
| Q2 2020 | $9,530,000 | – | 2,000,000 | – | 1.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
| RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
| VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
| RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
| DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
| Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
| Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
| GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
| Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |